Facebook (NASDAQ:FB) has elected University of California, San Francisco (UCSF) Chancellor Susan Desmond-Hellman, M.D., M.P.H., to its Board of Directors.
In the press release, founder and CEO Mark Zuckerberg said: "Sue has a great track record of building and managing a diverse set of organizations, so her insights will be valuable as we continue to expand into new areas".
Currently, she oversees all aspects of UCSF's strategy and operations. But in the past, she served as President of Product Development at biotechnology company Genentech, to bring several cancer drugs to market. During her 14 years with the company, she was responsible for the company's pre-clinical and clinical development, process research and development, business development, and product portfolio management.
In addition, Desmond-Hellmann is on the board of directors for Proctor & Gamble, and serves as a trustee for the Howard Hughes Medical Institute.
Aside from Desmond-Hellmann, Facebook's current board members are: Mark Zuckerberg; Marc L. Andreessen, Andreessen Horowitz; Erskine B. Bowles, president emeritus, University of North Carolina; James W. Breyer, Accel Partners; Donald E. Graham, chairman and CEO, The Washington Post Company (NYSE:GHC); Reed Hastings, chairman and CEO, Netflix (NASDAQ:NFLX); Sheryl Sandberg, chief operating officer, Facebook; and Peter A. Thiel, Founders Fund.